SymBio shifts bendamustine's multiple myeloma focus to second-line use

SymBio Pharmaceuticals has begun a Phase II trial in Japan with its lead product bendamustine for the treatment of the refractory and relapsed forms of multiple myeloma.

The Japanese venture initiated another Phase II study in 2010 investigating the alkylating agent in combination with prednisolone as a potential first-line therapy for the cancer of white blood cells, but says it is now prioritising